A novel antibiotic based long-term model of ovine smoke inhalation injury and septic shock.
We modified our established and clinically relevant ARDS model of smoke inhalation injury and septic shock by administration of combined antibiotics (AB) such as piperacillin and ciprofloxacin, to more closely mimic the clinical intensive care setting. Twenty-three sheep were subjected to the injury, and allocated to four groups for a 96 h study period: sham (n=5 non-injured); control (n=6: injured); AB6h (n=6: injured, antibiotics started 6 h post-injury); AB12h (n=6: injured, antibiotics started 12 h post-injury). All sham animals survived 96 h. Control, AB6h, AB12h groups reached criteria of septic shock within 12 h post-injury. All controls died within 36 h. Eighty three percent of AB6h and fifty percent of AB12h survived 96 h. Median survival times were significantly improved in the treated groups compared with the control group: 24 h in control vs. 80.5 h in AB6h, and 65 h in AB12h animals. Combined ciprofloxacin and piperacillin therapy was effective, reduced nitric oxide production and mortality, and will allow future long-term studies in this model.
Nakano
Yoshimitsu
Y
Department of Anesthesiology, Investigational Intensive Care Unit, The University of Texas Medical Branch, Shriners Burns Hospital for Children, 601 Harborside Drive, Galveston, TX 77555-1102, USA. ynakanoprs@gmail.com
Maybauer
Marc O
MO
Maybauer
Dirk M
DM
Enkhbaatar
Perenlei
P
Traber
Daniel L
DL
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000175:diagnosis; D002939:Ciprofloxacin / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D009569:Nitric Oxide / Q000097:blood; D010878:Piperacillin / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000150:complications; D011550:Pseudomonas aeruginosa; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D012128:Respiratory Distress Syndrome / Q000209:etiology; D034561:Sheep, Domestic; D012772:Shock, Septic / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D015208:Smoke Inhalation Injury / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors
D000900:Anti-Bacterial Agents; D009569:Nitric Oxide; D002939:Ciprofloxacin; D010878:Piperacillin
Crit Care Med. 2001 Jul;29(7):1303-10
11445675
Intensive Care Med. 1996 May;22(5):387-94
8796388
Am J Respir Crit Care Med. 1998 Feb;157(2):531-9
9476869
Crit Care Med. 2002 Sep;30(9):2083-90
12352045
J Vet Pharmacol Ther. 2001 Jun;24(3):237-40
11442805
Ann Surg. 1987 Jan;205(1):82-7
3800465
J Surg Res. 1980 Aug;29(2):189-201
6997619
Am J Physiol. 1996 Jan;270(1 Pt 2):R207-16
8769804
Shock. 2005 Sep;24(3):226-31
16135961
Biochem Biophys Res Commun. 2003 Nov 21;311(3):754-8
14623337
Intensive Care Med. 2007 Jul;33(7):1219-1227
17503018
Crit Care Med. 2001 Jun;29(6):1109-15
11395584
Drugs. 1984 Nov;28(5):375-425
6391888
Shock. 1998 Dec;10(6):442-5
9872685
Chest. 2000 Jul;118(1):146-55
10893372
Chest. 1992 Jun;101(6):1644-55
1303622
Chest. 2001 Feb;119(2 Suppl):412S-418S
11171778
Crit Care Med. 2006 Sep;34(9):2432-8
16810106
Shock. 2005 Dec;24 Suppl 1:19-23
16374368
Drugs. 1996 Jun;51(6):1019-74
8736621
Crit Care Med. 2008 Jan;36(1):296-327
18158437
J Surg Res. 1990 Aug;49(2):186-96
2199735
Biochem Biophys Res Commun. 2004 May 7;317(3):945-9
15081431
Intensive Care Med. 2001 Feb;27(2):355-62
11396279
Shock. 2005 Dec;24 Suppl 1:82-7
16374378
Semin Respir Infect. 2000 Dec;15(4):287-98
11220411